{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:31:19Z","timestamp":1778628679832,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd013600.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000}}],"reference-count":348,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013600.pub3","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T18:20:49Z","timestamp":1602526849000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review"],"prefix":"10.1002","author":[{"given":"Khai Li","family":"Chai","sequence":"additional","affiliation":[{"name":"Transfusion Research Unit, School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J","family":"Valk","sequence":"additional","affiliation":[{"name":"Jon J van Rood Center for Clinical Transfusion Research; Sanquin\/Leiden University Medical Center; Leiden Netherlands"},{"name":"Department of Clinical Epidemiology; Leiden University Medical Center; Leiden Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Piechotta","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Kimber","sequence":"additional","affiliation":[{"name":"Systematic Review Initiative; NHS Blood and Transplant; Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Doree","sequence":"additional","affiliation":[{"name":"Systematic Review Initiative; NHS Blood and Transplant; Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica M","family":"Wood","sequence":"additional","affiliation":[{"name":"Transfusion Research Unit, School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail A","family":"Lamikanra","sequence":"additional","affiliation":[{"name":"Clinical, Research and Development; NHS Blood and Transplant; Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Roberts","sequence":"additional","affiliation":[{"name":"Systematic Review Initiative; NHS Blood and Transplant; Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"McQuilten","sequence":"additional","affiliation":[{"name":"Transfusion Research Unit, School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"So-Osman","sequence":"additional","affiliation":[{"name":"Sanquin Blood Bank; Amsterdam Netherlands"},{"name":"Erasmus Medical Centre; Rotterdam Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise J","family":"Estcourt","sequence":"additional","affiliation":[{"name":"Haematology\/Transfusion Medicine; NHS Blood and Transplant; Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"10.1002\/14651858.CD013600.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.amsu.2020.06.018","article-title":"A severe refractory COVID-19 patient responding to convalescent plasma; a case series","volume":"56","author":"Abdullah","year":"2020","journal-title":"Annals of Medicine and Surgery"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0002|cit2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102875","article-title":"Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study","author":"Abolghasemi","journal-title":"Transfusion and Apheresis Science"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0003|cit3","first-page":"11","article-title":"SARS-CoV-2 neutralizing antibody titers in convalescent plasma and recipients in New Mexico: an open treatment study in COVID-19 patients","volume":"11","author":"Bradfute","year":"2020","journal-title":"Journal of\u00a0 Infectious Diseases"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0004|cit4","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.20.20156398","article-title":"Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: a prospective study","author":"Donato","year":"2020","journal-title":"medRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0006|cit6","article-title":"The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study","author":"Duan","year":"2020","journal-title":"medRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Dulipsingh L Danyal I Crowell R Diffenderfer M Williams K Lima C SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma (preprint) SSRN [Preprint] 2020","DOI":"10.2139\/ssrn.3669324"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0008|cit8","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.01.20139857","article-title":"Convalescent plasma for COVID-19. A randomized clinical trial","author":"Gharbharan","year":"2020","journal-title":"medRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0009|cit9","first-page":"19","article-title":"Use of convalescent plasma in hospitalized patients with Covid-19 - case series","volume":"19","author":"Hegerova","year":"2020","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0010|cit10","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.21.20109512","article-title":"Treatment of 6 COVID-19 patients with convalescent plasma","author":"Jin","year":"2020","journal-title":"medRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0011|cit11","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.19.20135830","article-title":"Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the midwest","author":"Hartman","year":"2020","journal-title":"medRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0012|cit12","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.12.20099879","article-title":"Early safety indicators of COVID-19 convalescent plasma in 5,000 patients","author":"Joyner","year":"2020","journal-title":"medRxiv [Preprint]"},{"issue":"9","key":"10.1002\/14651858.CD013600.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.mayocp.2020.06.028","article-title":"Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients","volume":"95","author":"Joyner","year":"2020","journal-title":"Mayo Clinical Proceedings"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0014|cit14","article-title":"Effect of convalescent plasma on mortality among hospitalized\u00a0patients with COVID-19: initial three-month experience","author":"Joyner","year":"2020","journal-title":"medRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0015|cit15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial","author":"Li","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD013600.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jama.2020.12607","article-title":"Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19","volume":"324","author":"Liu","year":"2020","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0017|cit17","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.20.20102236","article-title":"Convalescent plasma treatment of severe COVID-19: a matched control study","author":"Liu","year":"2020","journal-title":"medRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0018|cit18","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.21.20132944","article-title":"Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial","author":"Madariaga","year":"2020","journal-title":"medRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0019|cit19","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3605131","article-title":"Integrated COVID-19 convalescent plasma treatment and antibody research program at a single academic medical center","author":"Madariaga","year":"2020","journal-title":"SSRN"},{"issue":"3","key":"10.1002\/14651858.CD013600.pub3-BIB0020|cit20","first-page":"159","article-title":"Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study","volume":"72","author":"Olivares-Gazca","year":"2020","journal-title":"Revista de Investigation Clinica"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0021|cit21","article-title":"Mortality reduction in 46 severe COVID-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial","author":"Perotti","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0022|cit22","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.26.20113373","article-title":"Mortality reduction in 46 severe COVID-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial","author":"Perotti","year":"2020","journal-title":"medRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0023|cit23","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-020-02384-2","article-title":"Plasma from donors recovered from the new coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol","author":"Perotti","journal-title":"Internal and Emergency Medicine"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0024|cit24","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.24.20121905","article-title":"The therapeutic effectiveness of convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq","author":"Rasheed","year":"2020","journal-title":"medRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0025|cit25","first-page":"11","article-title":"Treatment of COVID-19 patients with convalescent plasma reveals a signal of significantly decreased mortality","volume":"11","author":"Salazar","year":"2020","journal-title":"American Journal of Pathology"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0026|cit26","first-page":"23","article-title":"Improved clinical symptoms and mortality on severe\/critical COVID-19 patients utilizing convalescent plasma transfusion","volume":"23","author":"Xia","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD013600.pub3-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/infdis\/jiaa228","article-title":"Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients","volume":"222","author":"Zeng","year":"2020","journal-title":"Journal of Infectious Diseases"},{"issue":"14","key":"10.1002\/14651858.CD013600.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.3346\/jkms.2020.35.e149","article-title":"Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea","volume":"35","author":"Ahn","year":"2020","journal-title":"Journal of Korean Medical Science"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"e00221","DOI":"10.1016\/j.crwh.2020.e00221","article-title":"The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: a case report","volume":"27","author":"Anderson","year":"2020","journal-title":"Case Reports in Women's Health"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0030|cit30","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-020-00315-y","article-title":"Clinical features of COVID-19 in a young man with massive cerebral hemorrhage-case report","author":"Bao","journal-title":"SN Comprehensive Clinical Medicine"},{"issue":"27","key":"10.1002\/14651858.CD013600.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1556\/650.2020.31901","article-title":"Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary: the first two cases","volume":"161","author":"Bobek","year":"2020","journal-title":"Orvosi Hetilap"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0032|cit32","unstructured":"Tratamento farmacol\u00f3gico para casos internados com SARS-COV-2, do Hospital das Cl\u00ednicas da Faculdade de Medicina de Ribeir\u00e3o Preto da Universidade de S\u00e3o Paulo portalarquivos.saude.gov.br\/images\/pdf\/2020\/May\/11\/TratamentoFarmacologico-SARS-COV-2-HC.RP.pdfhttp:\/\/fi-admin.bvsalud.org\/document\/view\/27t7v"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0033|cit33","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15910","article-title":"How did we rapidly implement a convalescent plasma program?","author":"Budhai","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0034|cit34","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102848","article-title":"Convalescent plasma from COVID 19 patients enhances intensive care unit survival rate. A preliminary report","author":"Cantore","journal-title":"Transfusion and Apheresis Science"},{"issue":"3","key":"10.1002\/14651858.CD013600.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"ofaa102","DOI":"10.1093\/ofid\/ofaa102","article-title":"High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019","volume":"7","author":"Cao","year":"2020","journal-title":"Open Forum Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD013600.pub3-BIB0036|cit36","first-page":"240","article-title":"Pregnant women complicated with COVID-19: a clinical analysis of 3 cases","volume":"49","author":"Chen","year":"2020","journal-title":"Zhejiang da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences"},{"issue":"6","key":"10.1002\/14651858.CD013600.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/jmv.25755","article-title":"A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019","volume":"92","author":"Chen","year":"2020","journal-title":"Journal of Medical Virology"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0038|cit38","unstructured":"Cancelled, due to modify the protocol A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment& www.chictr.org.cn\/showproj.aspx?proj=50258"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0039|cit39","unstructured":"Cancelled by investigator. A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient www.chictr.org.cn\/showproj.aspx?proj=50290"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0040|cit40","unstructured":"Combination of tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19) www.chictr.org.cn\/showproj.aspx?proj=50380"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0041|cit41","first-page":"27","article-title":"Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery","volume":"27","author":"Clark","year":"2020","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0042|cit42","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102821","article-title":"Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis","author":"\u00c7\u0131nar","journal-title":"Transfusion and Apheresis Science"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0043|cit43","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.15.043364","article-title":"Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent plasma using a coronavirus antigen microarray","author":"Assis","year":"2020","journal-title":"bioRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.07.029017","article-title":"Currently available intravenous immunoglobulin (Gamunex-C and Flebogamma\u00a9 DIF) contains antibodies reacting against SARS-CoV-2 antigens","author":"D\u00edez","year":"2020","journal-title":"bioRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1017\/S0950268820001351","article-title":"Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the Dakotas","volume":"148","author":"Enzmann","year":"2020","journal-title":"Epidemiology and Infection"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102867","article-title":"Life-saving effect of convalescent plasma treatment in covid-19 disease: clinical trial from eastern Anatolia","author":"Erkurt","journal-title":"Transfusion and Apheresis Science"},{"issue":"1","key":"10.1002\/14651858.CD013600.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.22514\/sv.2020.16.0027","article-title":"Recovery from critical COVID-19 despite delays in diagnosis and respiratory treatment: a cautionary tale","volume":"16","author":"Fan","year":"2020","journal-title":"Signa Vitae"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0048|cit48","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102866","article-title":"First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia","author":"Figlerowicz","journal-title":"Transfusion and Apheresis Science"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0049|cit49","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12940","article-title":"Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy","author":"Franchini","journal-title":"Vox Sanguinis"},{"issue":"3","key":"10.1002\/14651858.CD013600.pub3-BIB0050|cit50","first-page":"100174","article-title":"Convalescent plasma for coronavirus disease 2019 in pregnancy: a case report and review","volume":"2","author":"Grisolia","year":"2020","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemep.2020.100564","article-title":"Convalescent plasma to treat COVID-19: its challenges in Iraq situation","author":"Hashim","journal-title":"Ethics, Medicine and Public Health"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0052|cit52","first-page":"16","article-title":"Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin","volume":"16","author":"Hu","year":"2020","journal-title":"European Heart Journal"},{"issue":"26","key":"10.1002\/14651858.CD013600.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.3346\/jkms.2020.35.e239","article-title":"Convalescent plasma therapy in coronavirus disease 2019: a case report and suggestions to overcome obstacles","volume":"35","author":"Im","year":"2020","journal-title":"Journal of Korean Medical Science"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0054|cit54","unstructured":"A trial evaluating treatments for suspected coronavirus infection in people aged 50 years and above with pre-existing conditions and those aged 65 years and above www.isrctn.com\/ISRCTN86534580"},{"issue":"7","key":"10.1002\/14651858.CD013600.pub3-BIB0055|cit55","first-page":"312","article-title":"Critical illness due to COVID-19: a description of the surge in a single center in Sioux Falls","volume":"73","author":"Jamous","year":"2020","journal-title":"South Dakota Medicine"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"e14025","DOI":"10.1111\/ctr.14025","article-title":"Convalescent plasma therapy: helpful treatment of COVID-19 in a kidney transplant recipient presenting with severe clinical manifestation and complex complications","author":"Jiang","journal-title":"Clinical Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD013600.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"547","DOI":"10.21037\/atm.2020.04.20","article-title":"Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China","volume":"8","author":"Jiang","year":"2020","journal-title":"Annals of Translational Medicine"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0058|cit58","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102871","article-title":"Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma","author":"Karatas","journal-title":"Transfusion and Apheresis Science"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0059|cit59","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102820","article-title":"Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma","author":"Kong","journal-title":"Transfusion and Apheresis Science"},{"issue":"6","key":"10.1002\/14651858.CD013600.pub3-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jfma.2020.04.023","article-title":"Application of plasma exchange in association with higher dose CVVH in cytokine storm complicating COVID-19","volume":"119","author":"Lin","year":"2020","journal-title":"Journal of the Formosan Medical Association"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15975","article-title":"Lessons learned from early compassionate use of convalescent plasma on critically ill patients with COVID-19","author":"Liu","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.14.20144469","article-title":"Initial experience in Mexico with convalescent plasma in COVID-19 patients with severe respiratory failure, a retrospective case series","author":"Martinez-Resendez","year":"2020","journal-title":"medRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0063|cit63","doi-asserted-by":"crossref","unstructured":"McCuddy M Kelkar P Zhao Y Wicklund D Acute demyelinating encephalomyelitis (ADEM) in COVID-19 infection: a case series medRxiv [Preprint] 2020 10.1101\/2020.07.15.20126730","DOI":"10.1101\/2020.07.15.20126730"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0064|cit64","unstructured":"Ministerio de salud - Instituto Nacional de Salud Lineamientos t\u00e9cnicos para uso de plasma convaleciente en pacientes con COVID-19 fi-admin.bvsalud.org\/document\/view\/nruba 2020 1 20"},{"issue":"8","key":"10.1002\/14651858.CD013600.pub3-BIB0065|cit65","first-page":"2793","article-title":"Rapid recovery of a SARS-CoV-2 infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma","volume":"8","author":"Mira","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology: In Practice"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0066|cit66","unstructured":"The efficacy of intravenous immunoglobulin therapy for severe 2019-nCoV infected pneumonia clinicaltrials.gov\/ct2\/show\/NCT04261426"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0067|cit67","unstructured":"Convalescent plasma to stem coronavirus: a randomized, blinded phase 2 study comparing the efficacy and safety human coronavirus immune plasma (HCIP) vs. control (SARS-CoV-2 non-immune plasma) among adults exposed to COVID-19 clinicaltrials.gov\/show\/NCT04323800"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0068|cit68","unstructured":"Convalescent plasma to limit coronavirus associated complications: an open label, phase 2A study of high-titer anti-SARS-CoV-2 plasma in hospitalized patients with COVID-19 clinicaltrials.gov\/show\/NCT04325672"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0069|cit69","unstructured":"COVID-19 plasma collection clinicaltrials.gov\/show\/NCT04344015"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0070|cit70","unstructured":"Prevention of SARS-CoV-2 in hospital workers exposed to the virus clinicaltrials.gov\/show\/NCT04344379"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0071|cit71","unstructured":"COVID-19 plasma collection clinicaltrials.gov\/ct2\/show\/NCT04344977"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0072|cit72","unstructured":"Polyvalent immunoglobulin in COVID-19 related ARDS ClinicalTrials.gov\/show\/NCT04350580"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0073|cit73","unstructured":"Plasma collection from convalescent and\/or immunized donors for the treatment of COVID-19 clinicaltrials.gov\/show\/NCT04360278"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0074|cit74","unstructured":"Host-pathogen interactions, immune response, and clinical prognosis at COVID-19 - the CoVUm trial clinicaltrials.gov\/show\/NCT04368013"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0075|cit75","first-page":"15","article-title":"COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma","volume":"15","author":"Niu","year":"2020","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0076|cit76","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.07.20056440","article-title":"Convalescent plasma to treat COVID-19: Chinese strategy and experiences","author":"Pei","year":"2020","journal-title":"medRxiv [Preprint]"},{"issue":"1","key":"10.1002\/14651858.CD013600.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s13287-020-01802-8","article-title":"A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report","volume":"11","author":"Peng","year":"2020","journal-title":"Stem Cell Research and Therapy"},{"issue":"0","key":"10.1002\/14651858.CD013600.pub3-BIB0078|cit78","first-page":"E004","article-title":"The report of two cases infection with novel coronavirus (2019-NCcoV) after kidney transplantation and the association literature analyzation","volume":"41","author":"Qiu","year":"2020","journal-title":"Chinese Journal of Organ Transplantation"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0079|cit79","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.13.092619","article-title":"Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals","author":"Robbiani","year":"2020","journal-title":"bioRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.05.014","article-title":"Treatment of COVID-19 patients with convalescent plasma","author":"Salazar","journal-title":"American Journal of\u00a0\u00a0Pathology"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0081|cit81","doi-asserted-by":"crossref","unstructured":"Salazar E Perez KK Ashraf M Chen J Castillo B Christensen PA Treatment of COVID-19 patients with convalescent plasma in Houston, Texas medRxiv [Preprint] 2020 10.1101\/2020.05.08.20095471","DOI":"10.1101\/2020.05.08.20095471"},{"issue":"16","key":"10.1002\/14651858.CD013600.pub3-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD013600.pub3-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"105974","DOI":"10.1016\/j.ijantimicag.2020.105974","article-title":"Successful treatment of plasma exchange followed by intravenous immunoglobulin in a critically ill patient with 2019 novel coronavirus infection","volume":"56","author":"Shi","year":"2020","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1080\/14767058.2020.1797669","article-title":"ADRS due to COVID-19 in midterm pregnancy: successful management with plasma transfusion and corticosteroids","author":"Soleimani","journal-title":"Journal of Maternal-Fetal & Neonatal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013600.pub3-BIB0085|cit85","first-page":"e9693","article-title":"Acute kidney injury in COVID-19 pneumonia: a single-center\u00a0experience in Bahrain","volume":"12","author":"Taher","year":"2020","journal-title":"Cureus"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.22.20040071","article-title":"A special case of COVID-19 with long duration of viral shedding for 49 days","author":"Tan","year":"2020","journal-title":"medRxiv [Preprint]"},{"issue":"0","key":"10.1002\/14651858.CD013600.pub3-BIB0087|cit87","first-page":"E005","article-title":"Two clinical cases of novel coronavirus pneumonia (NCP) in renal transplant recipients","volume":"41","author":"Tu","year":"2020","journal-title":"Chinese Journal of Organ Transplantation"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3389\/fphar.2020.00966","article-title":"Convalescent plasma coupled with medications for the treatment of a severe COVID-19 patient: drugs analysis and pharmaceutical care based on the newly established guidelines for COVID-19 remedy","volume":"11","author":"Wang","year":"2020","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0089|cit89","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.06.012","article-title":"Successful use of COVID-19 convalescent plasma in a patient recently treated for follicular lymphoma","author":"Wright","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"issue":"2","key":"10.1002\/14651858.CD013600.pub3-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jinf.2020.03.044","article-title":"Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19","volume":"81","author":"Xie","year":"2020","journal-title":"Journal of Infection"},{"issue":"1","key":"10.1002\/14651858.CD013600.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12985-020-01354-6","article-title":"Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report","volume":"17","author":"Xu T","year":"2020","journal-title":"Virology Journal"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0092|cit92","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3576894","article-title":"Clinical characteristics and convalescent plasma therapy in severe and critically ill COVID-19 patients","author":"Yang","year":"2020","journal-title":"Social Science Research Network"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0093|cit93","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25882","article-title":"Treatment with convalescent plasma for COVID-19 patients in Wuhan, China","author":"Ye","journal-title":"Journal of Medical Virology"},{"issue":"1","key":"10.1002\/14651858.CD013600.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.chest.2020.03.039","article-title":"Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection","volume":"158","author":"Zhang","year":"2020","journal-title":"Chest"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0095|cit95","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.03.039","article-title":"Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection","author":"Zhang","journal-title":"Chest"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0096|cit96","doi-asserted-by":"publisher","DOI":"10.18632\/aging.103102","article-title":"Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19","author":"Zhang","journal-title":"Aging"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Agarwal A \u00a0Kumar G Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial) medRxiv [Preprint] 2020 10.1101\/2020.09.03.20187252","DOI":"10.1101\/2020.09.03.20187252"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0098|cit98","unstructured":"Study to assess the efficacy and safety of convalescent plasma in moderate COVID-19 disease ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=43149"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.26.20182444","article-title":"Convalescent plasma for COVID-19: a multicenter, randomized clinical trial","author":"\u00a0Ramos-Martinez","year":"2020","journal-title":"medRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0100|cit100","unstructured":"Effect of convalescent plasma in COVID-19 patients ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=43039"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0101|cit101","unstructured":"Evaluation of safety and efficacy of convalescent plasma in COVID-19 patients ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=42849"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0102|cit102","unstructured":"A phase II, open label, randomized controlled trial to assess the safety and efficacy of convalescent plasma to limit COVID-19 associated complications ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=43332"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0103|cit103","unstructured":"An open label randomised control trial on passive immunization with convalescent plasma in severe COVID-19 disease ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=43251"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0104|cit104","unstructured":"Convalescent plasma treatment trial in COVID 19 patients ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=43752"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0105|cit105","unstructured":"Study to assess the safety and efficacy of convalescent plasma on outcome of COVID-19 associated complications ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=43703"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0106|cit106","unstructured":"A phase II, open label, randomized controlled trial to assess the safety and efficacy of convalescent plasma in severe COVID-19 patients ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=43005"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0107|cit107","unstructured":"Effect of convalescent plasma in COVID-19 patients ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=44478"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0108|cit108","unstructured":"Plasma therapy in corona patients(Severe COVID-19) ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=44667"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0109|cit109","unstructured":"Efficacy and safety of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19): a prospective cohort study www.chictr.org.cn\/showproj.aspx?proj=49533"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0110|cit110","unstructured":"A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19) www.chictr.org.cn\/showproj.aspx?proj=49777"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0111|cit111","unstructured":"Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19) www.chictr.org.cn\/showproj.aspx?proj=49544"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0112|cit112","unstructured":"Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19) www.chictr.org.cn\/showproj.aspx?proj=50059"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0113|cit113","unstructured":"Study on the application of convalescent plasma therapy in severe COVID-19 www.chictr.org.cn\/showproj.aspx?proj=50727"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0114|cit114","unstructured":"Convalescent plasma for the treatment of common COVID-19: a prospective randomized controlled trial www.chictr.org.cn\/showproj.aspx?proj=50537"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0115|cit115","unstructured":"A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19) www.chictr.org.cn\/showproj.aspx?proj=50696"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0116|cit116","unstructured":"The efficacy of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19): a pragmatic, prospective cohort study www.chictr.org.cn\/showproj.aspx?proj=50254"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0117|cit117","unstructured":"The efficacy and safety of convalescent plasma therapy in novel coronavirus pneumonia (COVID-19): a medical records based retrospective cohort study www.chictr.org.cn\/showproj.aspx?proj=55194"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0118|cit118","unstructured":"A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19 www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-001310-38"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0119|cit119","unstructured":"The effect of convalescent plasma therapy on patients with 19-COVID en.irct.ir\/trial\/47594"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0120|cit120","unstructured":"Therapeutic effects of plasma of recovered people from COVID-19 on hospitalized patients with this disease en.irct.ir\/trial\/46931"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0121|cit121","unstructured":"Comparison of the therapeutic effect of convalescent plasma and plasma-derived immunoglobulin-enriched solution on COVID-19 patients en.irct.ir\/trial\/46424"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0122|cit122","unstructured":"Efficacy and safety of convalescent plasma in the treatment of COVID-19 en.irct.ir\/trial\/46973"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0123|cit123","unstructured":"Effect of COVID 19 survivors plasma in COVID 19 patients with ARDS en.irct.ir\/trial\/47058"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0124|cit124","unstructured":"Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in COVID-19 en.irct.ir\/trial\/47212"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0125|cit125","unstructured":"Treatment of COVID-19 patients with convalescent plasma en.irct.ir\/trial\/48493"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0126|cit126","unstructured":"Using blood plasma to develop passive immunity to coronavirus in Ecuador www.isrctn.com\/ISRCTN85216856"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0127|cit127","unstructured":"Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP) NCT02735707"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0128|cit128","unstructured":"Treatment of acute severe COVID-19 with immunoglobulin from cured COVID-19 patients www.chictr.org.cn\/showproj.aspx?proj=51072"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0129|cit129","unstructured":"An exploratory clinical study on the treatment of acute severe 2019-nCoV pneumonia with immunoglobulin from cured 2019-nCoV pneumonia patients clinicaltrials.gov\/show\/NCT04264858"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0130|cit130","unstructured":"The efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19): an observational study clinicaltrials.gov\/show\/NCT04292340"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0131|cit131","unstructured":"Investigating effect of convalescent plasma on COVID-19 patients outcome: a clinical trial clinicaltrials.gov\/show\/NCT04327349"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0132|cit132","unstructured":"Convalescent plasma for patients with COVID-19: a pilot study clinicaltrials.gov\/show\/NCT04332380"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0133|cit133","unstructured":"Convalescent plasma for patients with COVID-19: a randomized, open label, parallel, controlled clinical study clinicaltrials.gov\/show\/NCT04332835"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0134|cit134","unstructured":"Evaluating convalescent plasma to decrease coronavirus associated complications. A phase I study comparing the efficacy and safety of high-titer anti-Sars-CoV-2 plasma vs best supportive care in hospitalized patients with interstitial pneumonia due to COVID-19 clinicaltrials.gov\/show\/NCT04333251"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0135|cit135","unstructured":"Phase 1 study to evaluate the safety of convalescent plasma as an adjuvant therapy in patients with SARS-CoV-2 infection clinicaltrials.gov\/show\/NCT04333355"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0136|cit136","unstructured":"Expanded access to convalescent plasma for the treatment of patients with COVID-19 clinicaltrials.gov\/show\/NCT04338360"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0137|cit137","unstructured":"Convalescent plasma vs. standard plasma for COVID-19 clinicaltrials.gov\/show\/NCT04344535"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0138|cit138","unstructured":"Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2020-001367-88-DK"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0139|cit139","unstructured":"Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia (CCAP) clinicaltrials.gov\/show\/NCT04345289"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0140|cit140","unstructured":"Convalescent plasma therapy vs. SOC for the treatment of COVID19 in hospitalized patients (ConPlas-19) clinicaltrials.gov\/show\/NCT04345523"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0141|cit141","unstructured":"Anti COVID-19 convalescent plasma therapy clinicaltrials.gov\/show\/NCT04345679"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0142|cit142","unstructured":"Efficacy of convalescent plasma to treat COVID-19 patients, a nested trial in the CORIMUNO-19 cohort clinicaltrials.gov\/show\/NCT04345991"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0143|cit143","unstructured":"Efficacy of convalescent plasma therapy in severely sick COVID-19 patients clinicaltrials.gov\/show\/NCT04346446"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0144|cit144","unstructured":"Convalescent antibodies infusion in critically ill COVID 19 patients clinicaltrials.gov\/ct2\/show\/NCT04346589"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0145|cit145","unstructured":"Potential efficacy of convalescent plasma to treat severe COVID-19 and patients at high risk of developing severe COVID-19 clinicaltrials.gov\/show\/NCT04347681"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0146|cit146","unstructured":"Convalescent plasma for hospitalized adults with COVID-19 respiratory illness (CONCOR-1) clinicaltrials.gov\/show\/NCT04348656"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0147|cit147","unstructured":"Plasma rich antibodies from recovered patients from COVID19 clinicaltrials.gov\/show\/NCT04348877"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0148|cit148","unstructured":"Experimental use of convalescent plasma for passive immunization in current COVID-19 pandemic in Pakistan in 2020 clinicaltrials.gov\/show\/NCT04352751"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0149|cit149","unstructured":"Convalescent plasma in ICU patients with COVID-19-induced respiratory failure clinicaltrials.gov\/show\/NCT04353206"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0150|cit150","unstructured":"A study evaluating the efficacy and safety of high-titer anti-SARS-CoV-2 plasma in hospitalized patients with COVID-19 infection clinicaltrials.gov\/ct2\/show\/NCT04354831"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0151|cit151","unstructured":"Convalescent plasma vs. placebo in emergency room patients with COVID-19 clinicaltrials.gov\/ct2\/show\/NCT04355767"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0152|cit152","unstructured":"COVID-19 plasma in treatment of COVID-19 patients clinicaltrials.gov\/ct2\/show\/NCT04355897"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0153|cit153","unstructured":"Convalescent plasma for ill patients by COVID-19 clinicaltrials.gov\/show\/NCT04356482"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0154|cit154","unstructured":"Convalescent plasma trial in COVID -19 patients clinicaltrials.gov\/show\/NCT04356534"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0155|cit155","unstructured":"Expanded access to convalescent plasma to treat and prevent pulmonary complications associated with COVID-19 clinicaltrials.gov\/show\/NCT04358211"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0156|cit156","unstructured":"Convalescent plasma compared to the best available therapy for the treatment of SARS-CoV-2 pneumonia clinicaltrials.gov\/show\/NCT04358783"},{"issue":"1","key":"10.1002\/14651858.CD013600.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/s13063-020-04504-x","article-title":"Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial","volume":"21","author":"Eckhardt","year":"2020","journal-title":"Trials"},{"issue":"1","key":"10.1002\/14651858.CD013600.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1186\/s13063-020-04422-y","article-title":"Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial","volume":"21","author":"Eckhardt","year":"2020","journal-title":"Trials"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0159|cit159","unstructured":"Plasma therapy of COVID-19 in critically ill patients clinicaltrials.gov\/show\/NCT04359810"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0160|cit160","unstructured":"Treatment of COVID-19 with anti-SARS-CoV-2 convalescent plasma (ASCoV2CP) clinicaltrials.gov\/show\/NCT04360486"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0161|cit161","unstructured":"Evaluation of SARS-CoV-2 (COVID-19) antibody-containing plasma therapy clinicaltrials.gov\/show\/NCT04361253"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0162|cit162","unstructured":"Passive immunity trial of Nashville II clinicaltrials.gov\/show\/NCT04362176"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0163|cit163","unstructured":"Arkansas expanded access COVID-19 convalescent plasma treatment program clinicaltrials.gov\/ct2\/show\/NCT04363034"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0164|cit164","unstructured":"Convalescent plasma to limit COVID-19 complications in hospitalized patients clinicaltrials.gov\/show\/NCT04364737"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0165|cit165","unstructured":"Convalescent plasma for COVID-19 clinicaltrials.gov\/show\/NCT04365439"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0166|cit166","unstructured":"Clinical trial to evaluate the efficacy of treatment with hyperimmune plasma obtained from convalescent antibodies of COVID-19 infection clinicaltrials.gov\/show\/NCT04366245"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0167|cit167","unstructured":"Convalescent plasma for the treatment of patients with COVID-19 clinicaltrials.gov\/show\/NCT04372368"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0168|cit168","unstructured":"Efficacy of convalescent plasma therapy in the early care of COVID-19 patients clinicaltrials.gov\/show\/NCT04372979"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0169|cit169","unstructured":"Convalescent plasma to limit SARS-CoV-2 associated complications clinicaltrials.gov\/show\/NCT04373460"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0170|cit170","unstructured":"SARSCoV2 (COVID-19) convalescent plasma (CP) expanded access protocol (EAP) clinicaltrials.gov\/show\/NCT04374370"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0171|cit171","unstructured":"A phase II, open label, randomized controlled trial to assess the safety and efficacy of convalescent plasma to limit COVID-19 associated complications clinicaltrials.gov\/show\/NCT04374487"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0172|cit172","unstructured":"Early transfusIon of convalescent plasma in elderly COVID-19 patients to prevent disease progression clinicaltrials.gov\/show\/NCT04374526"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0173|cit173","unstructured":"Convalescent plasma for treatment of COVID-19 patients with pneumonia clinicaltrials.gov\/show\/NCT04374565"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0174|cit174","unstructured":"Efficacy and safety of early COVID-19 convalescent plasma in patients admitted for COVID-19 infection clinicaltrials.gov\/show\/NCT04375098"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0175|cit175","unstructured":"Convalescent plasma collection and treatment in pediatrics and adults clinicaltrials.gov\/show\/NCT04376034"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0176|cit176","unstructured":"Exchange transfusion versus plasma from convalescent patients with methylene blue in patients with COVID-19 clinicaltrials.gov\/show\/NCT04376788"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0177|cit177","unstructured":"Efficacy of human coronavirus-immune convalescent plasma for the treatment of COVID-19 disease in hospitalized children clinicaltrials.gov\/show\/NCT04377568"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0178|cit178","unstructured":"Human convalescent plasma for high risk children exposed or infected with SARS-CoV-2 clinicaltrials.gov\/show\/NCT04377672"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0179|cit179","unstructured":"Effectiveness and safety of convalescent plasma therapy on COVID-19 patients with acute respiratory distress syndrome clinicaltrials.gov\/show\/NCT04380935"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0180|cit180","unstructured":"Convalescent plasma vs human immunoglobulin to treat COVID-19 pneumonia clinicaltrials.gov\/show\/NCT04381858"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0181|cit181","unstructured":"Randomised evaluation of COVID-19 therapy (RECOVERY) clinicaltrials.gov\/ct2\/show\/NCT04381936"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0182|cit182","unstructured":"Convalescent plasma and placebo for the treatment of COVID-19 severe pneumonia clinicaltrials.gov\/show\/NCT04383535"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0183|cit183","unstructured":"Clinical study for efficacy of anti-corona VS2 immunoglobulins prepared from COVID19 convalescent plasma prepared by VIPS mini-pool IVIG medical devices in prevention of SARS-CoV-2 infection in high risk groups as well as treatment of early cases of COVID clinicaltrials.gov\/show\/NCT04383548"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0184|cit184","unstructured":"Convalescent plasma for treatment of COVID-19: an exploratory dose identifying study clinicaltrials.gov\/show\/NCT04384497"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0185|cit185","unstructured":"COVID19-convalescent plasma for treating patients with active symptomatic COVID 19 infection (FALP-COVID) clinicaltrials.gov\/show\/NCT04384588"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0186|cit186","unstructured":"Hyperimmune plasma in patients with COVID-19 severe infection clinicaltrials.gov\/show\/NCT04385043"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0187|cit187","unstructured":"Inactivated convalescent plasma as a therapeutic alternative in patients COVID-19 clinicaltrials.gov\/show\/NCT04385186"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0188|cit188","unstructured":"Convalescent plasma for patients with COVID-19 clinicaltrials.gov\/show\/NCT04385199"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0189|cit189","unstructured":"Safety and efficacy of convalescent plasma transfusion for patients with SARS-CoV-2 infection clinicaltrials.gov\/show\/NCT04388410"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0190|cit190","unstructured":"COVID-19 convalescent plasma for mechanically ventilated population clinicaltrials.gov\/show\/NCT04388527"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0191|cit191","unstructured":"Convalescent plasma for the treatment of COVID-19 clinicaltrials.gov\/show\/NCT04389710"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0192|cit192","unstructured":"Amotosalen-ultraviolet a pathogen-inactivated convalescent plasma in addition to best supportive care and antiviral therapy on clinical deterioration in adults presenting with moderate to severe COVID-19 clinicaltrials.gov\/show\/NCT04389944"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0193|cit193","unstructured":"Convalescent plasma as treatment for acute coronavirus disease (COVID-19) clinicaltrials.gov\/show\/NCT04390178"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0194|cit194","unstructured":"Convalescent plasma for COVID-19 close contacts clinicaltrials.gov\/ct2\/show\/NCT04390503"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0195|cit195","unstructured":"Convalescent plasma for the treatment of severe SARS-CoV-2 (COVID-19) clinicaltrials.gov\/show\/NCT04391101"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0196|cit196","unstructured":"A phase 2 study of COVID 19 convalescent plasma in high risk patients with COVID 19 infection clinicaltrials.gov\/show\/NCT04392232"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0197|cit197","unstructured":"Hyperimmune convalescent plasma in moderate and severe COVID-19 disease clinicaltrials.gov\/show\/NCT04392414"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0198|cit198","unstructured":"Transfusion of convalescent plasma for the early treatment of pneumonIa due to SARSCoV2 clinicaltrials.gov\/show\/NCT04393727"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0199|cit199","unstructured":"Convalescent plasma compared to anti-COVID-19 human immunoglobulin and standard treatment (TE) in hospitalized patients clinicaltrials.gov\/show\/NCT04395170"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0200|cit200","unstructured":"Efficacy and safety of COVID-19 convalescent plasma clinicaltrials.gov\/show\/NCT04397523"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0201|cit201","unstructured":"COVID-19 convalescent plasma for the treatment of hospitalized patients with pneumonia caused by SARS-CoV-2 clinicaltrials.gov\/show\/NCT04397757"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0202|cit202","unstructured":"Convalescent plasma therapy in severe COVID-19 infection clinicaltrials.gov\/show\/NCT04403477"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0203|cit203","unstructured":"Convalescent plasma to limit coronavirus associated complications clinicaltrials.gov\/show\/NCT04404634"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0204|cit204","unstructured":"Convalescent plasma of COVID-19 to treat SARS-COV-2 a randomized double blind 2 center trial (CPC-SARS) clinicaltrials.gov\/show\/NCT04405310"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0205|cit205","unstructured":"Convalescent plasma therapy in patients with COVID-19 clinicaltrials.gov\/show\/NCT04407208"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0206|cit206","unstructured":"Use of convalescent plasma for COVID-19 clinicaltrials.gov\/show\/NCT04408040"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0207|cit207","unstructured":"Convalescent plasma for the treatment of patients with severe COVID-19 infection clinicaltrials.gov\/show\/NCT04408209"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0208|cit208","unstructured":"Feasibility study of anti-SARS-CoV-2 plasma transfusions in COVID-19 patients with SRD clinicaltrials.gov\/show\/NCT04411602"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0209|cit209","unstructured":"COVID-19 convalescent plasma (CCP) transfusion clinicaltrials.gov\/show\/NCT04412486"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0210|cit210","unstructured":"Treatment of patients with COVID-19 with convalescent plasma clinicaltrials.gov\/show\/NCT04415086"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0211|cit211","unstructured":"A trial of convalescent plasma for hospitalized adults with acute COVID-19 respiratory illness clinicaltrials.gov\/show\/NCT04418518"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0212|cit212","unstructured":"Convalescent antibodies infusion in COVID 19 patients clinicalrrials.gov\/show\/NCT04418531"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0213|cit213","unstructured":"Investigational COVID-19 convalescent plasma infusion for severely or life-threateningly ill COVID-19 patients clinicaltrials.gov\/show\/NCT04420988"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0214|cit214","unstructured":"Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients clinicaltrials.gov\/show\/NCT04421404"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0215|cit215","unstructured":"Effectiveness and safety of convalescent plasma in patients with high-risk COVID-19 clinicaltrials.gov\/show\/NCT04425837"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0216|cit216","unstructured":"Efficacy of convalescent plasma therapy in patients with COVID-19 clinicaltrials.gov\/show\/NCT04425915"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0217|cit217","unstructured":"Standard or convalescent plasma in patients with recent onset of COVID-19 respiratory failure clinicaltrials.gov\/show\/NCT04428021"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0218|cit218","unstructured":"Donated antibodies working against nCoV clinicaltrials.gov\/show\/NCT04429854"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0219|cit219","unstructured":"Treatment of severe and critical COVID-19 pneumonia with convalescent plasma clinicaltrials.gov\/show\/NCT04432103"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0220|cit220","unstructured":"Antibody-level based analysis of COVID convalescent serum (ABACCuS) clinicaltrials.gov\/ct2\/show\/NCT04432272"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0221|cit221","unstructured":"A clinical trial of convalescent plasma compared to best supportive care for treatment of patients with severe COVID-19 https:\/\/Cclinicaltrials.gov\/show\/NCT04433910"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0222|cit222","unstructured":"Evaluating the efficacy of convalescent plasma in symptomatic outpatients infected with COVID-19 clinicaltrials.gov\/show\/NCT04438057"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0223|cit223","unstructured":"Use of convalescent plasma for treatment of patients with COVID-19 infection clinicaltrials.gov\/show\/NCT04438694"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0224|cit224","unstructured":"Convalescent plasma as a possible treatment for COVID-19 clinicaltrials.gov\/show\/NCT04442191"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0225|cit225","unstructured":"Effectiveness of convalescent immune plasma therapy clinicaltrials.gov\/show\/NCT04442958"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0226|cit226","unstructured":"Experimental expanded access treatment with convalescent plasma for the treatment of patients with COVID-19 clinicaltrials.gov\/show\/NCT04445207"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0227|cit227","unstructured":"Statistical and epidemiological study based on the use of convalescent plasma for the management of patients with COVID-19 clinicaltrials.gov\/show\/NCT04452812"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0228|cit228","unstructured":"Convalescent plasma as treatment for subjects with early COVID-19 infection clinicaltrials.gov\/show\/NCT04456413"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0229|cit229","unstructured":"Convalescent plasma in pediatric COVID-19 clinicaltrials.gov\/ct2\/show\/NCT04458363"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0230|cit230","unstructured":"COVID-19 convalescent plasma as prevention and treatment for children with underlying medical conditions clinicaltrials.gov\/show\/NCT04462848"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0231|cit231","unstructured":"\"NORPLASMA\" COVID-19 convalescent plasma treatment monitoring study clinicaltrials.gov\/show\/NCT04463823"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0232|cit232","unstructured":"Administration of anti-SARS-CoV-2 convalescent plasma in hospitalized, non-ICU patients with COVID-19 clinicaltrials.gov\/show\/NCT04467151"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0233|cit233","unstructured":"Treatment of critically ill patients with COVID-19 with convalescent plasma clinicaltrials.gov\/show\/NCT04468009"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0234|cit234","unstructured":"An observational cohort trial of outcomes and antibody responses following treatment with COVID19 convalescent plasma in hospitalized COVID-19 patients clinicaltrials.gov\/show\/NCT04471051"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0235|cit235","unstructured":"Expanded access to convalescent plasma for treatment of COVID-19 clinicaltrials.gov\/show\/NCT04472572"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0236|cit236","unstructured":"COVID-19 convalescent plasma treatment in SARS-CoV-2 infected patients: multicenter interventional study clinicaltrials.gov\/show\/NCT04474340"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0237|cit237","unstructured":"Convalescent plasma treatment in COVID-19 clinicaltrials.gov\/show\/NCT04476888"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0238|cit238","unstructured":"Prevention of severe COVID-19 in infected elderly by early administration of convalescent plasma with high-titers of antibody against SARS-CoV2 clinicaltrials.gov\/show\/NCT04479163"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0239|cit239","unstructured":"Australasian COVID-19 trial (ASCOT) clinicaltrials.gov\/show\/NCT04483960"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0240|cit240","unstructured":"Investigational treatments for COVID-19 in tertiary care hospital of Pakistan clinicaltrials.gov\/show\/NCT04492501"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0241|cit241","unstructured":"Peruconplasma: evaluating the use of convalescent plasma as management of COVID-19 www.clinicaltrials.gov\/ct2\/show\/NCT04497324"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0242|cit242","unstructured":"Analysis of coronavirus disease 19 (COVID-19) convalescent plasma clinicaltrials.gov\/show\/NCT04497779"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0243|cit243","unstructured":"Open-label treatment of severe coronavirus disease 2019 (COVID-19) with convalescent plasma clinicaltrials.gov\/show\/NCT04502472"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0244|cit244","unstructured":"Convalescent plasma in the early treatment of high-risk patients with SARS-CoV-2 (COVID-19) infection clinicaltrials.gov\/show\/NCT04513158"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0245|cit245","unstructured":"Therapeutic use of convalescent plasma in the treatment of patients with moderate to severe COVID-19 clinicaltrials.gov\/show\/NCT04516811"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0246|cit246","unstructured":"Convalescent plasma for COVID-19 patients clinicaltrials.gov\/show\/NCT04516954"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0247|cit247","unstructured":"A randomized, double blinded clinical trial of convalescent plasma compared to standard plasma for treatment of hospitalized non-ICU patients with COVID-19 infections www.trialregister.nl\/trial\/8633"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0248|cit248","unstructured":"Effect of convalescent plasma in patients with severe COVID-19 www.ensaiosclinicos.gov.br\/rg\/RBR-4vm3yy\/"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0249|cit249","unstructured":"Effect of COVID-19 convalescent plasma produced by HEMOPE: a randomized study, with a comparative group in several centers www.ensaiosclinicos.gov.br\/rg\/RBR-7jqpnw\/"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0250|cit250","unstructured":"Plasma treatment to asymptomatic patient with COVID-19 infection rpcec.sld.cu\/en\/trials\/RPCEC00000323-En"},{"issue":"4","key":"10.1002\/14651858.CD013600.pub3-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0252|cit252","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.13.990226","article-title":"Reinfection could not occur in SARS-CoV-2 infected rhesus macaques","author":"Bao","year":"2020","journal-title":"bioRxiv [Preprint]"},{"issue":"2","key":"10.1002\/14651858.CD013600.pub3-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10067-019-04832-7","article-title":"Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review","volume":"39","author":"Baudel","year":"2020","journal-title":"Clinical Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD013600.pub3-BIB0254|cit254","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S2213-2600(17)30174-1","article-title":"Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study","volume":"5","author":"Beigel","year":"2017","journal-title":"Lancet Respiratory Medicine"},{"issue":"11","key":"10.1002\/14651858.CD013600.pub3-BIB0255|cit255","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-2600(19)30199-7","article-title":"Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial","volume":"7","author":"Beigel","year":"2019","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0256|cit256","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19 - preliminary report","author":"Beigel","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013600.pub3-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI138745","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","volume":"130","author":"Bloch","year":"2020","journal-title":"Journal of Clinical Investigation"},{"issue":"2","key":"10.1002\/14651858.CD013600.pub3-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2249.2003.02199.x","article-title":"Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin","volume":"133","author":"Brennan","year":"2003","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0259|cit259","article-title":"Adjusted fatality rates of COVID19 pandemic: a comparison across countries","author":"Canelo-Aybar","year":"2020","journal-title":"medRxiv [Preprint]"},{"issue":"4","key":"10.1002\/14651858.CD013600.pub3-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"Journal of Clinical Investigation"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0261|cit261","unstructured":"Centers for Disease Control and Prevention (CDC) Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) Available at www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-guidance-management-patients.html"},{"issue":"4","key":"10.1002\/14651858.CD013600.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD013600.pub3-BIB0263|cit263","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3343\/alm.2016.36.4.393","article-title":"Possible transfusion-related acute lung injury following convalescent plasma transfusion in a patient with Middle East respiratory syndrome","volume":"36","author":"Chun","year":"2016","journal-title":"Annals of Laboratory Medicine"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0264|cit264","unstructured":"Core outcome set developers\u2019 response to COVID-19 (2nd April 2020) Available at www.comet-initiative.org\/Studies\/Details\/1538"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0265|cit265","unstructured":"Veritas Health Innovation Covidence"},{"issue":"6","key":"10.1002\/14651858.CD013600.pub3-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/lt.25756","article-title":"Coronaviruses and immunosuppressed patients: the facts during the third epidemic","volume":"26","author":"D\u2019Antiga","year":"2020","journal-title":"Liver Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD013600.pub3-BIB0267|cit267","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S2213-2600(19)30253-X","article-title":"Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial","volume":"7","author":"Fern\u00e1ndez-Cruz","year":"2019","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0268|cit268","doi-asserted-by":"crossref","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch10"},{"issue":"18","key":"10.1002\/14651858.CD013600.pub3-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","article-title":"Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic","volume":"75","author":"Driggin","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD013600.pub3-BIB0270|cit270","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.iac.2008.06.004","article-title":"History of immunoglobulin replacement","volume":"28","author":"Eibl","year":"2008","journal-title":"Immunology and Allergy Clinics of North America"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0271|cit271","unstructured":"Eldridge S Campbell M Campbell M Dahota A Giraudeau B Higgins JT Revised Cochrane risk of bias tool for randomized trials (RoB 2.0) additional considerations for cluster-randomized trials Available from:\u00a0www.riskofbias.info\/welcome\/rob-2-0-tool\/archive-rob-2-0-cluster-randomized-trials-2016"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0272|cit272","unstructured":"What study designs can be considered for inclusion in an EPOC review and what should they be called? EPOC Resources for review authors Available from epoc.cochrane.org\/resources\/epoc-resources-review-authors"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0273|cit273","unstructured":"Recommendations for investigational COVID-19 convalescent plasma Available from:\u00a0www.fda.gov\/vaccines-blood-biologics\/investigational-new-drug-ind-or-device-exemption-ide-process-cber\/recommendations-investigational-covid-19-convalescent-plasma"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0274|cit274","article-title":"COVID-19 in immunocompromised hosts: what we know so far","author":"Fung","year":"2020","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0275|cit275","first-page":"458-64","article-title":"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1-30, 2020","volume":"69","author":"Garg","year":"2020","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0276|cit276","unstructured":"GetData Graph Digitizer 2.26 S. Fedorov 2019"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0277|cit277","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0279|cit279","unstructured":"Higgins JP Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0280|cit280","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0281|cit281","doi-asserted-by":"crossref","unstructured":"Higgins JPT Eldridge S Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook.","DOI":"10.1002\/9781119536604.ch23"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0282|cit282","doi-asserted-by":"crossref","unstructured":"Higgins JP Savovi\u0107 J Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch8"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0283|cit283","doi-asserted-by":"crossref","unstructured":"Higgins JP Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"issue":"11","key":"10.1002\/14651858.CD013600.pub3-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.3201\/eid1111.040659","article-title":"Neutralizing antibody response and SARS severity","volume":"11","author":"Ho","year":"2005","journal-title":"Emerging Infectious Diseases"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0285|cit285","article-title":"Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report","author":"Horby","year":"2020","journal-title":"medRxiv [Preprint]"},{"issue":"10223","key":"10.1002\/14651858.CD013600.pub3-BIB0286|cit286","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD013600.pub3-BIB0287|cit287","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1378\/chest.12-2907","article-title":"Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection","volume":"144","author":"Hung","year":"2013","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD013600.pub3-BIB0288|cit288","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0567","article-title":"Olfactory dysfunction in the COVID-19 outbreak","volume":"30","author":"Izquierdo-Dominguez","year":"2020","journal-title":"Journal of Investigational Allergology & Clinical Immunology"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0289|cit289","article-title":"Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy","author":"Joyner","year":"2020","journal-title":"medRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0290|cit290","article-title":"Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience","author":"Joyner","year":"2020","journal-title":"medRxiv [Preprint]"},{"issue":"12","key":"10.1002\/14651858.CD013600.pub3-BIB0291|cit291","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.3346\/jkms.2020.35.e137","article-title":"Understanding and interpretation of case fatality rate of coronavirus disease 2019","volume":"35","author":"Choe","year":"2020","journal-title":"Journal of Korean Medical Science"},{"issue":"1-2","key":"10.1002\/14651858.CD013600.pub3-BIB0292|cit292","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.virusres.2011.09.022","article-title":"Immune responses to influenza virus infection","volume":"162","author":"Kreijtz","year":"2011","journal-title":"Virus Research"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0293|cit293","doi-asserted-by":"publisher","first-page":"M20","DOI":"10.7326\/M20-0504","article-title":"The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application","author":"Lauer","year":"2020","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0294|cit294","doi-asserted-by":"crossref","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Metzendorf MI Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch4"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0295|cit295","doi-asserted-by":"crossref","unstructured":"Li T Higgins JP Deeks JJ Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"issue":"3","key":"10.1002\/14651858.CD013600.pub3-BIB0296|cit296","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013600.pub3-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013600.pub3-BIB0298|cit298","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0299|cit299","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","author":"McGuinness","year":"2020","journal-title":"Research\u00a0Synthesis Methods"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0300|cit300","doi-asserted-by":"crossref","unstructured":"McKenzie JE Brennan SE Ryan RE Thomson HJ Johnston RV Thomas J Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch3"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0301|cit301","unstructured":"Microsoft Corporation, available at: office.microsoft.com\/excel Mircosoft Excel 2018"},{"issue":"1","key":"10.1002\/14651858.CD013600.pub3-BIB0302|cit302","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1440-1843.2006.00783.x","article-title":"Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance","volume":"11","author":"Mo","year":"2006","journal-title":"Respirology"},{"issue":"10","key":"10.1002\/14651858.CD013600.pub3-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD013600.pub3-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/clinids\/19.3.500","article-title":"Antibody-dependent enhancement of infection and the pathogenesis of viral disease","volume":"19","author":"Morens","year":"1994","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD013600.pub3-BIB0305|cit305","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008205.pub3","article-title":"Hepatic late adverse effects after antineoplastic treatment for childhood cancer","author":"Mulder","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD013600.pub3-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/vox.12573","article-title":"Transfusion-related acute lung injury risk mitigation: an update","volume":"112","author":"Otrock","year":"2017","journal-title":"Vox Sanguinis"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1111\/j.1537-2995.2012.03663.x","article-title":"Adverse effects of plasma transfusion","volume":"52 Suppl 1","author":"Pandey","year":"2012","journal-title":"Transfusion"},{"issue":"24","key":"10.1002\/14651858.CD013600.pub3-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"10","key":"10.1002\/14651858.CD013600.pub3-BIB0309|cit309","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.3201\/eid2210.160706","article-title":"Persistence of antibodies against Middle East respiratory syndrome coronavirus","volume":"22","author":"Payne","year":"2016","journal-title":"Emerging Infectious Disease Journal"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0310|cit310","unstructured":"Piechotta V Chai KL Valk SJ Kimber C Monsef I Doree C Supplementary dataset. ROB 2 assessments for convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review zenodo.org\/record\/3994365#.X3s3EGgzZaQ 10.5281\/zenodo.3994365"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0311|cit311","doi-asserted-by":"crossref","unstructured":"Reeves BC Deeks JJ Higgins JP Shea B Tugwell P Wells GA Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch24"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0312|cit312","unstructured":"The Cochrane Collaboration Review Manager Web (RevMan Web) 2019"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0313|cit313","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202003.0138.v1","article-title":"Medical countermeasures analysis of 2019-nCoV and vaccine risks for antibody-dependent enhancement (ADE)","author":"Ricke","year":"2020","journal-title":"Preprints [Preprint]"},{"issue":"6","key":"10.1002\/14651858.CD013600.pub3-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/infdis\/171.6.1387","article-title":"Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum","volume":"171","author":"Robbins","year":"1995","journal-title":"Journal of Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD013600.pub3-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1423-0410.2010.01374.x","article-title":"A comparison of methods of pathogen inactivation of FFP","volume":"100","author":"Rock","year":"2011","journal-title":"Vox Sanguinis"},{"issue":"12","key":"10.1002\/14651858.CD013600.pub3-BIB0316|cit316","first-page":"2000256","article-title":"Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020","volume":"25","author":"Russell","year":"2020","journal-title":"Euro Surveillance"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jclinepi.2018.01.012","article-title":"GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence","volume":"111","author":"Sch\u00fcnemann","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0319|cit319","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org\/handbook Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD013600.pub3-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","article-title":"Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors","volume":"121","author":"Sekul","year":"1994","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jclinepi.2019.10.015","article-title":"GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and evidence profiles","volume":"118","author":"Skoetz","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD013600.pub3-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfusion Medicine Reviews"},{"issue":"8","key":"10.1002\/14651858.CD013600.pub3-BIB0325|cit325","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3760\/cma.j.issn.0254-6450.2020.02.003","article-title":"Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) - China","volume":"2","author":"Team NCPERE","year":"2020","journal-title":"China CDC Weekly"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"2","key":"10.1002\/14651858.CD013600.pub3-BIB0327|cit327","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.34172\/jrip.2020.19","article-title":"COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment","volume":"9","author":"Tolouian","year":"2020","journal-title":"Journal of Renal Injury Prevention"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0328|cit328","unstructured":"COVID-19 expanded access program Available from www.uscovidplasma.org"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0329|cit329","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202004.0023.v1","article-title":"Kinins and cytokines in COVID-19: a comprehensive pathophysiological approach","author":"Van de Veerdonk","year":"2020","journal-title":"Preprints [Preprint]"},{"issue":"5","key":"10.1002\/14651858.CD013600.pub3-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"e02015","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry","volume":"94","author":"Wan","year":"2020","journal-title":"Journal of Virology"},{"issue":"2","key":"10.1002\/14651858.CD013600.pub3-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbrc.2014.07.090","article-title":"Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins","volume":"451","year":"2014","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0332|cit332","unstructured":"World Health Organization (WHO) Cumulative number of reported probable cases of SARS www.who.int\/csr\/sars\/country\/2003_07_11\/en\/"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0333|cit333","unstructured":"World Health Organization (WHO) Middle East respiratory syndrome coronavirus (MERS-CoV) www.who.int\/emergencies\/mers-cov\/en\/"},{"key":"#cr-split#-10.1002\/14651858.CD013600.pub3-BIB0334|cit334.1","unstructured":"World Health Organization (WHO) Report of the WHO-China Joint Mission on coronavirus disease 2019 (COVID-19)"},{"key":"#cr-split#-10.1002\/14651858.CD013600.pub3-BIB0334|cit334.2","unstructured":"February 2020 www.who.int\/docs\/default-source\/coronaviruse\/who-china-joint-mission-on-covid-19-final-report"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0335|cit335","unstructured":"World Health Organization (WHO) Rolling updates on coronavirus diseases (COVID-19) www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/events-as-they-happen"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0336|cit336","unstructured":"World Health Organization (WHO) Coronavirus disease (COVID-19) situation report-209; 16 August 2020 www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200707-covid-19-sitrep-209.pdf"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0337|cit337","doi-asserted-by":"crossref","unstructured":"World Health Organization (WHO) Clinical management of severe acute respiratory infection (SARI) when COVID19 disease is suspected: interim guidance World Health Organization 2020 WHO\/2019-nCoV\/clinical\/2020.4","DOI":"10.15557\/PiMR.2020.0003"},{"issue":"8","key":"10.1002\/14651858.CD013600.pub3-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection","year":"2020","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0339|cit339","unstructured":"World Health Organization COVID-19 Therapeutic Trial Synopsis Available from\u00a0www.who.int\/blueprint\/priority-diseases\/key-action\/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0340|cit340","article-title":"OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients","author":"Williamson","year":"2020","journal-title":"medRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0341|cit341","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","author":"Wu","year":"2020","journal-title":"JAMA Internal Medicine"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0342|cit342","article-title":"Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications","author":"Wu","year":"2020","journal-title":"medRxiv [Preprint]"},{"issue":"4","key":"10.1002\/14651858.CD013600.pub3-BIB0343|cit343","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0344|cit344","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.02.20030189","article-title":"Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019","author":"Zhao","year":"2020","journal-title":"medRxiv [Preprint]"},{"key":"10.1002\/14651858.CD013600.pub3-BIB0345|cit345","unstructured":"Piechotta V Valk SJ \u00a0Chai KL Wood EM \u00a0Lamikanra A \u00a0Kimber C Safety and effectiveness of convalescent plasma or hyperimmune globulin for people with COVID-19: a rapid review available at:\u00a0doi.org\/10.17605\/OSF.IO\/DWF53 2020 10.17605\/OSF.IO\/DWF53"},{"issue":"7","key":"10.1002\/14651858.CD013600.pub3-BIB0346|cit346","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013600.pub2","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review","author":"Piechotta","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD013600.pub3-BIB0347|cit347","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013600","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review","author":"Valk","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd013600.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T01:52:19Z","timestamp":1669168339000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013600.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Haematology Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":348,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013600.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD013600.pub4","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]}}}